Latest Articles

Publication Date
All News Scientific
Emmy Nominee Dies of Endometrial Cancer: Jackie Burch Was 74 - PopCulture.com

Emmy Nominee Dies of Endometrial Cancer: Jackie Burch Was 74 PopCulture.com

Published: Oct. 20, 2025, 4:32 a.m.
Read Full Article
Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer - CUREtoday.com

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer CUREtoday.com

Published: Oct. 19, 2025, 6:39 p.m.
Read Full Article
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - CancerNetwork

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer CancerNetwork

Published: Oct. 19, 2025, 4:40 p.m.
Read Full Article
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - cancernetwork.com

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer cancernetwork.com

Published: Oct. 19, 2025, 4:40 p.m.
Read Full Article
Exclusive: Sid Mukherjee’s Faeth nets $25M for endometrial cancer study - Endpoints News

Exclusive: Sid Mukherjee’s Faeth nets $25M for endometrial cancer study Endpoints News

Published: Oct. 19, 2025, 9:01 a.m.
Read Full Article
Giorgio Bogani: New Insights into POLE-Mutated Endometrial Cancer with Nodal Involvement - Oncodaily

Giorgio Bogani: New Insights into POLE-Mutated Endometrial Cancer with Nodal Involvement Oncodaily

Published: Oct. 18, 2025, 10:08 p.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Lelezard

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Lelezard

Published: Oct. 18, 2025, 12:47 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - The AI Journal

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer The AI Journal

Published: Oct. 18, 2025, 10:20 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - GlobeNewswire

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer GlobeNewswire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!